Avraham Pharma Raises $4.5M

September 18, 2014 | Israeli pharmaceutical company Avraham Pharma raised $4.5 million from Yissum Research Development, Pontifax, Clal Biotechnology Industries, Integra Holdings and the Technion Research and Development Foundation, among others. Following this current investment round, Yissum and Integra Holdings will hold 46 percent of the shares in Avraham Pharma. According to Avraham Pharma, the company will use the investment to advance a Phase IIb study of Ladostigil, a molecular treatment for the treatment of mild cognitive impairment and early stages of Alzheimer’s. Avraham Pharma was founded in 2010 and to date has raised $18 million for the development of its novel drug therapies for the treatment and prevention of neurodegenerative disease.